Page 56 - Read Online

Page 16 of 17 Balakrishnan et al. J Cancer Metastasis Treat 2022;8:27 https://dx.doi.org/10.20517/2394-4722.2022.33

86. Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination
immunotherapy. Nat Rev Clin Oncol 2016;13:273-90. DOI
87. Lumachi F, Luisetto G, Basso SM, Basso U, Brunello A, Camozzi V. Endocrine therapy of breast cancer. Curr Med Chem
2011;18:513-22. DOI PubMed
88. Shree T, Olson OC, Elie BT, et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes
Dev 2011;25:2465-79. DOI PubMed PMC
89. Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R. Molecular testing for BRAF mutations to inform melanoma
treatment decisions: a move toward precision medicine. Mod Pathol 2018;31:24-38. DOI PubMed PMC
90. Mok S, Tsoi J, Koya RC, et al. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
BMC Cancer 2015;15:356. DOI PubMed PMC
91. Sakai Y, Miyazawa M, Komura T, et al. Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in
murine pancreatic cancer models. Cancer Sci 2019;110:903-12. DOI PubMed PMC
92. Shiao SL, Ruffell B, DeNardo DG, Faddegon BA, Park CC, Coussens LM. TH2-Polarized CD4(+) T cells and macrophages limit
efficacy of radiotherapy. Cancer Immunol Res 2015;3:518-25. DOI PubMed PMC
93. Cavnar MJ, Zeng S, Kim TS, et al. KIT oncogene inhibition drives intratumoral macrophage M2 polarization. J Exp Med
2013;210:2873-86. DOI PubMed PMC
94. Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG. Recruitment of myeloid but not endothelial precursor cells
facilitates tumor regrowth after local irradiation. Cancer Res 2010;70:5679-85. DOI
95. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64. DOI PubMed PMC
96. Peranzoni E, Ingangi V, Masetto E, Pinton L, Marigo I. Myeloid cells as clinical biomarkers for immune checkpoint blockade. Front
Immunol 2020;11:1590. DOI PubMed PMC
97. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
DOI PubMed PMC
98. Bjoern J, Juul Nitschke N, Zeeberg Iversen T, Schmidt H, Fode K, Svane IM. Immunological correlates of treatment and response in
stage IV malignant melanoma patients treated with Ipilimumab. Oncoimmunology 2016;5:e1100788. DOI PubMed PMC
99. Lopatina T, Koni M, Grange C, et al. IL-3 signalling in the tumour microenvironment shapes the immune response via tumour
endothelial cell-derived extracellular vesicles. Pharmacol Res 2022;179:106206. DOI PubMed
100. Retseck J, Nasr A, Lin Y, et al. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses
in patients with melanoma. J Transl Med 2018;16:184. DOI PubMed PMC
101. Tzeng A, Diaz-Montero CM, Rayman PA, et al. Immunological correlates of response to immune checkpoint inhibitors in metastatic
urothelial carcinoma. Target Oncol 2018;13:599-609. DOI PubMed
102. Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol 2018;19:108-19. DOI PubMed
PMC
103. Lin EY, Gouon-evans V, Nguyen AV, Pollard JW. The macrophage growth factor CSF-1 in mammary gland development and tumor
progression. J Mammary Gland Biol Neoplasia 2002;7:147-62. DOI PubMed
104. Leuschner F, Dutta P, Gorbatov R, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol
2011;29:1005-10. DOI PubMed PMC
105. Conde J, Bao C, Tan Y, et al. Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumour-
associated macrophages and cancer cells. Adv Funct Mater 2015;25:4183-94. DOI PubMed PMC
106. Cieslewicz M, Tang J, Yu JL, et al. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival.
Proc Natl Acad Sci USA 2013;110:15919-24. DOI PubMed PMC
107. Jose A, Labala S, Ninave KM, Gade SK, Venuganti VVK. Effective skin cancer treatment by topical co-delivery of curcumin and
STAT3 siRNA using cationic liposomes. AAPS PharmSciTech 2018;19:166-75. DOI PubMed
108. Jahchan NS, Mujal AM, Pollack JL, et al. Tuning the tumor myeloid microenvironment to fight cancer. Front Immunol
2019;10:1611. DOI PubMed PMC
109. Ban Y, Mai J, Li X, et al. Targeting autocrine CCL5-CCR5 axis reprograms immunosuppressive myeloid cells and reinvigorates
antitumor immunity. Cancer Res 2017;77:2857-68. DOI PubMed PMC
110. Stanley ER, Chitu V. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb Perspect Biol 2014;6:a021857-a021857. DOI
PubMed PMC
111. Chao MP, Jaiswal S, Weissman-Tsukamoto R, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers
and is counterbalanced by CD47. Sci Translat Med 2010:2. DOI PubMed PMC
112. Kharitonenkov A, Chen Z, Sures I, Wang H, Schilling J, Ullrich A. A family of proteins that inhibit signalling through tyrosine
kinase receptors. Nature 1997;386:181-6. DOI PubMed
113. Weiskopf K. Cancer immunotherapy targeting the CD47/SIRPα axis. Eur J Cancer 2017;76:100-9. DOI PubMed
114. Cekic C, Linden J. Purinergic regulation of the immune system. Nat Rev Immunol 2016;16:177-92. DOI PubMed
115. Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer 2018;6:57. DOI PubMed PMC
116. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-95. DOI PubMed
117. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.
Nature 1998;393:474-8. DOI PubMed